Labiotech.eu

News and Trends 15 Aug 2022

Aptinyx fibromyalgia drug misses endpoint

Biopharma company Aptinyx Inc. says its phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia did not achieve statistically significant separation from placebo on the study’s primary endpoint. “We are very disappointed that, despite the evidence of activity observed in a prior biomarker study in fibromyalgia patients, in this follow-up phase […]

August 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Aug 2022

Tetro Bio-Pharma enters subscription agreement following advice from Alpha Blue Ocean

Tetra Bio-Pharma Inc., a company working in cannabinoid-based drug discovery and development, has announced it has entered into a subscription agreement with investment vehicle Global Corporate Finance Opportunities 16 (GCFO 16). The announcement came yesterday (August 11) after Alpha Blue Ocean (ABO) advised the partnership whereby Canadian-based Tetra agrees to issue investor GCFO 16 senior […]

August 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 12 Aug 2022

argenx secures European Commission approval for generalized myasthenia gravis treatment

Dutch immunology company argenx says the European Commission (EC) has granted marketing authorization for VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. The approval is applicable to all 27 European Union (EU) Member States plus Iceland, […]

August 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Aug 2022

Beyond Biotech podcast 9: ARCH Venture Partners, Micropep, PTC Therapeutics, Valneva

On this week’s podcast, we have conversations with ARCH Venture Partners’ managing director Kristina Burow; founder and CEO of Micropep Thomas Laurent; Kylie O’Keefe, SVP, commercial & corporate strategy at PTC Therapeutics, and Juan Carlos Jaramillo, chief medical officer of Valneva. ARCH Venture Partners closes $2.97B biotech fund ARCH Venture Partners has announced the closing […]

August 12, 2022

More News! 12 Aug 2022

Planet’s plastic problem can be eased by enzyme engineering platform, researchers say

Steps have been taken to tackle the planet’s plastic problem by researchers from the Manchester Institute of Biotechnology (MIB). They have developed a new enzyme engineering platform to improve plastic degrading enzymes through directed evolution. The platform can successfully degrade polyethylene terephthalate (PET), the plastic commonly used in plastic bottles. Enzymatic recycling The researchers say […]

August 12, 2022 - 4 minutesmins - By Liza Laws

conveyor belt of medical vials for scale up production

News and Trends 11 Aug 2022

Regen BioPharma develops new approach for boosting CAR-T cell efficiency to treat solid tumors

Regen BioPharma, Inc. has filed with the United States Patent and Trademark Office a provisional U.S. patent application covering the company’s novel approach for enabling chimeric antigen receptor (CAR)-T cell-based therapies to kill solid tumors through prevention of a process called “T cell exhaustion.” CAR-T cells are effective at treating certain lymphomas and leukemias with […]

August 11, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 11 Aug 2022

First patient enrolled on Panbela’s trial for treatment of pancreatic cancer

Panbela Therapeutics, a U.S.-based clinical stage company, announced today (August 11) that it has enrolled its first patient in a global trial to evaluate a potential cure for pancreatic cancer. The trial referred to as ASPIRE will involve studying SBP-101, a treatment for metastatic pancreatic ductal adenocarcinoma. It is a randomized, double-blind placebo-controlled, trial with […]

August 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Aug 2022

Gemini Therapeutics and Disc Medicine announce merger agreement

Gemini Therapeutics and Disc Medicine have entered into a definitive merger agreement to combine in an all-stock transaction. The announcement came yesterday (August 10) and the combined company will focus on advancing Disc’s pipeline of hematology programs and is expected to operate under the name Disc Medicine Inc. upon shareholder approval. The work will include […]

August 11, 2022 - 2 minutesmins - By Liza Laws

News and Trends 11 Aug 2022

Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout

Synlogic, Inc. has announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks. The new candidate, SYNB2081, is a synthetic biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following the investigational new drug candidate SYNB1353 for the potential […]

August 11, 2022 - 2 minutesmins - By Jim Cornall

beta-thalassemia blood APS antiphospholipid syndrome

News and Trends 11 Aug 2022

Study of drug to treat porphyria disorders initiated by Disc Medicine

A phase 2 clinical study of bitopertin in patients with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) has been initiated by Disc Medicine. The announcement of the study, called BEACON, was made August 10. EPP or XLP belong to a group of the porphyria disorders, which are all characterized by abnormally high levels of chemicals, […]

August 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Aug 2022

Acquisition of TeneoTwo and its clinical-stage T-cell engager completed

AstraZeneca has said today (August 11) that it has completed its purchase of TeneoTwo including its B-cell non-Hodgkin lymphoma drug candidate. The company made an upfront payment of $100 million and then additional payments of up to $805 million contingent on research and development milestones as well as up to $360 million to TeneoTwo’s former […]

August 11, 2022 - 2 minutesmins - By Liza Laws

In Depth 11 Aug 2022

Biosecurity is synthetic biology’s most crucial ally

Synthetic biology has made it easier than ever to engineer organisms to serve our needs. But as the technology becomes widespread, concerns about its potential misuse arise. How can we ensure biosecurity without hindering the advance of synthetic biology? Biosecurity consists of the prevention of and response to the release of potentially harmful organisms. Now […]

August 11, 2022 - 6 minutesmins - By Kostas Vavitsas

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Aptinyx fibromyalgia drug misses endpoint

Tetro Bio-Pharma enters subscription agreement following advice from Alpha Blue Ocean

argenx secures European Commission approval for generalized myasthenia gravis treatment

Beyond Biotech podcast 9: ARCH Venture Partners, Micropep, PTC Therapeutics, Valneva

Planet’s plastic problem can be eased by enzyme engineering platform, researchers say

Regen BioPharma develops new approach for boosting CAR-T cell efficiency to treat solid tumors

First patient enrolled on Panbela’s trial for treatment of pancreatic cancer

Gemini Therapeutics and Disc Medicine announce merger agreement

Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout

Study of drug to treat porphyria disorders initiated by Disc Medicine

Acquisition of TeneoTwo and its clinical-stage T-cell engager completed

Biosecurity is synthetic biology’s most crucial ally

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!